Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 14/20 | 0.57 |
| ▸ | CASP6 | P55212 | 13/20 | 0.57 |
| ▸ | CASP8 | Q14790 | 13/20 | 0.57 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367055 | 1.00 | CASP3 (0.57) | CASP3CASP6CASP8CASP1CTSB | |
| SCHEMBL8247253 | 0.92 | CASP3 (0.67) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL7745119 | 0.92 | CASP3 (0.67) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL18863053 | 0.91 | CASP3 (0.55) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL9415817 | 0.86 | CASP3 (0.46) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL645918 | 0.84 | CASP3 (0.57) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL13914069 | 0.82 | CASP3 (0.50) | CASP3CASP6CASP8CASP1CTSB | |
| SCHEMBL30472164 | 0.81 | CASP3 (0.47) | CASP3CASP6CASP8CASP1CTSB | |
| SCHEMBL13197161 | 0.80 | CASP1 (0.59) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL8402109 | 0.80 | CASP1 (0.59) | CASP3CASP6CASP8CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130012683-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8303973-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100268288-A1 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20050149157-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050143817-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051316-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051871-A2 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051483-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051444-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051451-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051232-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | CASP3 3094/4885CASP6 1496/4885CASP8 3077/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | CASP3 2260/4885CASP6 1691/4885CASP8 1297/4885 |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | MMP1, CDKN1A, MKI67 | CASP3 998/4885CASP6 608/4885CASP8 585/4885 |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ILK, PLOD3, MMP1 | CASP3 400/4885CASP6 314/4885CASP8 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.